SCHEMBL19959784

SCHEMBL19959784

O=P(c1cccnc1)(c1ccc2ccccc2c1)c1ccc2c(c1)nc1c3ccccc3c3ccccc3n21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 5/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
MEN1 O00255 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP11B1 P15538 2/20 0.33
CYP17A1 P05093 1/20 0.33
CYP19A1 P11511 1/20 0.33
CYP11B2 P19099 1/20 0.33
TP53 P04637 2/20 0.32
MAPT P10636 2/20 0.32
USP2 O75604 1/20 0.32
LMNA P02545 3/20 0.31
KDM4E B2RXH2 2/20 0.31
POLB P06746 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19959790 0.93 SMN1; SMN2 (0.37) CYP2C9SMN1; SMN2MEN1NPC1RAB9A
SCHEMBL19959821 0.93 KDM4E (0.35) CYP2C9SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL19959804 0.92 CYP2C9 (0.38) CYP2C9SMN1; SMN2MEN1NPC1RAB9A
SCHEMBL19959809 0.91 CYP2C9 (0.38) CYP2C9SMN1; SMN2MEN1NPC1RAB9A
SCHEMBL19959828 0.90 KDM4E (0.37) CYP2C9SMN1; SMN2MEN1NPC1RAB9A
SCHEMBL19959789 0.90 CYP2C9 (0.35) CYP2C9SMN1; SMN2MEN1NPC1RAB9A
SCHEMBL19959782 0.89 KDM4E (0.37) CYP2C9SMN1; SMN2MEN1NPC1RAB9A
SCHEMBL19960138 0.88 CYP2C9 (0.32) CYP2C9SMN1; SMN2MEN1NPC1RAB9A
SCHEMBL19959865 0.87 KDM4E (0.35) CYP2C9SMN1; SMN2MEN1NPC1RAB9A
SCHEMBL19959791 0.85 CYP2C9 (0.37) CYP2C9SMN1; SMN2MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10700289-B2 Heterocyclic compound and organic light emitting element comprising same LG CHEM, LTD. (KR) 2020-06-30 US disclosed
US-20180076395-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-03-15 US disclosed
US-20180076395-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180076395-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME CRY1, CRY2, PER2 CYP2C9 143/4885SMN1; SMN2 3857/4885MEN1 885/4885
US-10700289-B2 Heterocyclic compound and organic light emitting element comprising same CRY1, CRY2, PER2 CYP2C9 143/4885SMN1; SMN2 3857/4885MEN1 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.